MTOR and gastric cancer: Besides, in gastric cancer (GC) cells, RHOA-Y42 mutations activate the PI3K-AKT-mTOR pathway, then increase the production of FAs that are more effectively consumed by Treg cells than cytotoxic T lymphocyte (CTL), generating an immunosuppressive TME that underlies resistance to immune checkpoint blockade [175].